Special Issue "Kinase Inhibitors in Cancer and Central Nervous System"

A special issue of Scientia Pharmaceutica (ISSN 2218-0532).

Deadline for manuscript submissions: 28 March 2019

Special Issue Editor

Guest Editor
Prof. Dr. Thierry Besson

Normandie Univ, Univ Rouen; INSA Rouen, CNRS, Laboratoire COBRA UMR6014Bâtiment IRCOF, 1 rue Tesnière, F-76821 Mont Saint-Aignan Cedex, France
Website | E-Mail
Interests: N,O,S-heterocycles for therapeutic applications; microwave-assisted chemistry; active drugs for cancer and central nervous system; cancer and CNS drugs

Special Issue Information

Dear Colleagues,

Protein kinases catalyse protein phosphorylation—a key cellular regulatory mechanism which is frequently dysregulated in human diseases. Kinases have consequently been linked to the progress of a variety of diseases, including cancer and neurodegenerative disorders. Therefore, the search for therapeutic inhibitors of specific kinases has been developed in the last three decades as a major approach to discovering new therapeutic drugs. Initially focused on the discovery, optimization, and characterization of tyrosine kinase inhibitors and on cancer indications, the field is now rapidly expanding towards serine/threonine kinases and essentially all other therapeutic indications as neurodegenerative diseases (Alzheimer’s disease, Down syndrome).

In this Special Issue, our goal is to highlight papers describing an intended inhibition of specific kinases, although they are not always the initial and main target of the compounds tested. In silico molecular design connected with the development of chemical syntheses and pertinent comments on the forthcoming applications of these inhibitors will be particularly appreciated.

Prof. Dr. Thierry Besson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Scientia Pharmaceutica is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • neurodegenerative diseases
  • Down syndrome
  • cancer
  • kinase inhibitors
  • in silico design
  • multi-target drug ligand
  • cancer cell quiescence
  • chemical synthesis
  • tyrosine kinases
  • Ser/Thr kinases
  • dual-specificity tyrosine phosphorylation-regulated kinases

Published Papers

This special issue is now open for submission.
Back to Top